EAN 2025
Featured articles
Lecanemab in AD: not a paradigm shift, but a small step forward
EAN 2025 Highlights Podcast
CONTENTS
Online First
Epilepsy
SUDEP is an underreported cause of death in epilepsy patients
Stroke
Significant impact of implementing thrombectomy in Spanish stroke centres
Sleep
OX2R agonists are a promising causal treatment of narcolepsy
Neurologists must wake up to the importance of sleep
Infectious Diseases
Virus-specific T cells show promise in treating PML
Parkinson's disease
Encouraging results of adaptive DBS for Parkinson’s disease
Cognitive Impairment and Dementia
Dementia doubles the mortality risk 1 year after hip fracture
Lecanemab in AD: not a paradigm shift, but a small step forward
Headache and Migrane
GLP-1R agonists reduce migraine burden in obese patients
Occipital nerve stimulation is no more effective than placebo in cluster headache
Similar efficacy of anti-CGRP mAbs in short- and long-term migraine prevention
Why a good result of migraine treatment may not be good enough
Multiple Sclerosis
Rituximab does not halt progression in non-active secondary progressive MS
Real-world data confirms the effectiveness and safety of ofatumumab in MS
Comparable effectiveness and persistence of ocrelizumab and natalizumab
Muscle/Neuromuscular Disorders
Earlier add-on treatment in myasthenia gravis improves outcomes
Long-term benefits of cipa/mig in late-onset Pompe disease
Neuropathies
